Hello everyone. You have Stuart Gander here, CEO of Q-linea AB. And I'm joined by Christopher Samuelson, my CFO. Thank you for joining this Q4 report from Q-linea AB. Our year-end report for 2025.
Just a quick disclaimer up front on all forward-looking statements. We'll take that as read. So, a typical format for this presentation, as we've had in the past, I'll spend some time here just giving you an update on the commercial progress for the company, some of the context and dynamics we see in the market. Then we'll share a little bit of how our customers are seeing that with their patient impact.
And some of the evidence that's coming out of usage in the real world, which we're very excited about.
And then we'll start to look forward into 2026 before I'll hand over the reins to Christopher, who will walk through the financials in our quarterly report.
And as ever, we'll wrap up with some Q&A.
So with that, and for those who have very little time and just want the highlights. A few key messages to walk away from on this report. First of all, 2025 did generate significant growth in the top line. So we're more than 4x greater than the previous year. We're excited about that. And consumables revenue is obviously also growing and even faster year on year, which is great to see. It's being driven by the installation of the installed base, which I'll get to shortly.
We do see, and perhaps most importantly, that the commercial pipeline continues to expand and we are seeing it move and develop. I'll talk about that in more detail. And really, the exciting thing for us as we look forward is we expect the US to start converting at a faster rate. Post our FDA clearance for an expanded menu that we're expecting in the first half of 2026. So, obviously the pipeline we're tracking on both sides of the Atlantic, the US one being sizable, and we do see progression starting to unlock. Following that expanded menu, let's now address our internal initiatives. We've done a couple of things during 2025 that are going to materially impact our progress during this year. Firstly, we have fully now internalized our production of our consumables that is generating already a significant savings on a per unit cost of goods basis.
We will continue to see Cost of Goods declining through this year as both more of our improvement initiatives kick in, and also the scale effect realization of having our own control over production continues to drive benefits there.
And then we did a sizable restructuring at the back end of last year. The new organization formally went into place 1st of January.
So Christopher will talk a little bit about how that's affected our OPEX costs, which will now begin to decrease from Q1 and going forward. So we expect a material reduction in monthly opex through 2026. So those are the high level messages. I'll just give again, a little preamble for those who are new to Q-linea AB and rapid AST.
We consider ourselves a leader, if not the leader, in rapid antimicrobial susceptibility testing for primarily blood infection patients. Our flagship platform is the ASTar platform, which has a lot of very compelling benefits vis-a-vis other alternatives on the market and also vis-a-vis standard of care. And we synthesize this down to a few key points here. We see ourselves as the only fully automated random access platform available all around the world. We have less than two minutes of hands-on time. It's extremely easy to use in the lab.
Very effective workflow. It integrates into any lab, and the test is highly predictable.
It always comes within six hours. Fully start to finish. All of the sample preparation steps are done on board this fully automated platform.
And so, what we anticipate in the market and are starting to see – which is driving our consumables growth and instrument placements through this year – is that the market will move from an established standard of care today, which typically takes 36 to 72 hours to get a blood infection patient a full AST result. And we will see that moving towards a much faster solution, which we call rapid AST.
And this will follow the most critical patients. First, obviously, the blood infection patients are amongst those. But there are other groups, cancer patients for example, pediatric patients, high acuity patients, and so on. And we already see interest and traction in those categories as well.
So, obviously the total potential here is greater than the complete sum of blood infection tests. But our focus right now is on those blood infections.
So that's driving the trend here. And it is, from my perspective, just a matter of time before rapid AST becomes the new standard of care and replaces the old systems.
So we tried to synthesize obviously a lot of dynamics through the year into how we see it. And I hope this picture starts to give some life to what we're seeing in numbers through 2025.
We tried to provide more and more visibility on how the pipeline was progressing. And we've talked a lot about movement here. And I'll get to how many instruments we expected to deploy versus what went into the market.
But obviously the pipeline, as we've talked about before, is driven by a very long cycle time, which is normal for our industry. 12 to 15, or even up to 18 months, is entirely normal to go from start to finish on placing a new instrument in the lab. Obviously, this is a new technology, so there's a lot of variability in that. In previous presentations, we've shown the full pipeline, including a very extensive list of labs that we're already engaging with. What we are trying to show here now is really the end of the funnel, the real tangible side of it.
Now, where we will focus through this year and give you more visibility. And it's really the evaluations that are contracted, planned or already in progress.
So those are customers that are physically touching the instrument or saying they want it in their lab to physically touch it and or they're already in contracting, which is the very last step. So they've already decided they want ASTar. And we're working through the terms, maybe some pricing, that type of thing. And you can see the graph here that has grown significantly through last year. And already, the 8083 represented here, based on our December last year performance, shows enough instruments to meet our plan for this year. These are all decisions that we would expect to be made during 2026. We may not win all of those, obviously, but we have a very strong track record once we get to this stage. I think I've referenced before that I would expect, at this stage of the game, to be getting north of three quarters of those if we hold our current win rates, so that, long story short, we can already see the deals we need to make the 2026 plan work.
In addition to that, we will of course add to this as we go forward. And we do see already that there will be a shortening of some cycle times, as characterized especially by Italy, which has already seen more and more customers coming directly to us, skipping some of the earlier steps, starting to skip the evaluation steps. This is something we would expect to also see towards the back end of this year in the US as we get a critical mass there. So we go from those in the pipeline into contracted ASTar units. This is our kind of headline number. And because that's a very tangible one, we define that as when we received a PO. So we shipped the instrument against that PO. Often we charge for the instrument or we start rental charges, or can start shipping, obviously the kits and so on.
So this is the real number that we want to track through it.
Here, obviously, we were giving a projection, if you will, for the end of the year. We wanted to get 30 or north of that. Obviously we talked a lot about the ASTar tender of nine units in Italy, which we were disappointed by the adjudication of that process.
That, to my understanding, remains a little bit open, but we've put very low visibility on those ones for now. Nonetheless, we did continue to grow our contracted units in Italy, which still achieved plan. I think we were short in two areas.
We were a little bit under in placements in mainland Europe. I'll talk about that in a little bit. But the main thing holding us back versus our plan number was the US. And this, I think, we just need to recognize is due to our initial FDA-cleared menu, which comprises the antimicrobials and pathogens clinicians can use on the platform, being smaller than our European one. And that was down to some technicalities of the R&D requirements for the clinical trial.
And we recognize that we had hoped that with our bridging strategy there, we would get more of the customers signed on and using the instrument. And we were also a little disappointed that many of them are just saying we want to go when you have the full menu. Now, the good news is we have already submitted that updated clinical trial to the FDA as of October last year. So we are now in the FDA review process, which is a clearly defined process and timeline. So we have good visibility that we should be getting that clearance, if not at the end of Q1, at least during the first half of Q2, which is when we plan against a full launch into the US market of our expanded menu. Can't say too much detail about that now, obviously, as it is an FDA review, but we do anticipate from the early feedback and conversation we're having that we will have a very compelling menu, especially vis a vis other alternatives on the market. So, we are having very open discussions with customers about how they want to get started once we have that clearance. So we have a queue lined up, if you will, to run against once that comes through. Hence, we expect the latter half of 2026 to really unlock for the US.
Then the next step of the journey here is ASTar and clinical use. There is a lag from when we get the Purchase Order and ship the instrument to when they are fully up and running and ready to go with a patient in the ward. A real live patient.
They typically do.
Obviously some installation and training activities. They need to link it to the LIS, the lab information system, so that can take some time. And then they may do a bit of a soft launch with some clinicians and patients, paying close attention to that initially before they go with the full patient base.
That's quite normal ramp up. We participate very closely in each step of the way. And typically that process is between 3 and 6 months. And we're seeing that now shorten again in mature places like Italy where there's more established experience with rapid AST and ASTar.
So we plan for something around that three-month gap from contracting to going into clinical use, and we'll continue to monitor that.
And obviously, then the next and key step for us in our business model is when those then turn into the pull-through on the patient testing. We do have a mixed model. In many cases, the customers do pay us for the instrument upfront. But currently, in the majority of cases, we place that instrument on a reagent rental contract or some form of rental agreement.
And then have pricing baked into the consumables. And here what you're seeing is that rolling 12-month increase in the test usage going up. And obviously that momentum will carry over into 2025 on the back of the 14 systems that are already in clinical use. And we'll start to turn on more and more systems. So that's the dynamic.
I think all of those are very strong curves.
You're talking, you know, 300, 400% increases obviously year on year. And we would expect those trends to more or less carry through into 2026. So that gets to a little bit of our outlook for this year and our run to breakeven. We have continuously held that 2027 is our breakeven year. That's in our long-term business plan. We're constantly calibrating our assumptions on pull-through, pricing, and gross margins, etc. And obviously, it bounces around a little bit here and there.
But the nice thing is we get more and more visibility, and that range of possible scenarios, let's say, is tightening up.
Right. We don't hide the fact we'd hope to emerge from 2025 with more instruments, again, with that caveat that there's a lot queued up in the US for the V2.
We do see that if those convert in 2026, we will achieve this number here, an additional 50 to 70 instruments during this year that we want to contract and get up and running. I think previously we said 60 to 90. So, there's some overlap in that range.
And just acknowledging that Q1 here in the US is likely to be a little lower as we wait for that V2, and then carrying into 2027 that momentum off the back of this year, more or less maintaining the Q4 pace through 2027, and then there's a range if that even accelerates from there. So that carries us past the breakeven point that we're really paying very close attention to.
So what is it that gives us some confidence that we're on track here? A number of things, really. Italy, we keep pointing out as our reference country. There are a few reasons why Italy is at the forefront.
I think the Italians in general are enthusiastic adopters of new technology and in the healthcare space.
So this is not totally unusual. But also they have a very high burden of antimicrobial resistance and the consequent impact on patients and budgets for the hospital.
And the country itself has been very progressive in defining guidelines and suggesting that hospitals and labs adopt the technology.
And we're seeing that not only in the placed instruments so far with Q-linea AB and with some of our competitors, but also in the outlook for the number of labs that we already have in various degrees of conversation with, and we would expect that many, if not most of these—we're talking several dozen—will convert over the next 12 to 24 months.
Right. So we would see Italy continuing to progress at a steady pace as it's done. Now, I've talked already about the US acceleration from Q2 driven by the approval of the menu. I think the other dynamic here that's a little bit special to the US, that's very powerful is often when we do a contract, we do it with an Integrated Delivery Network, which can be a cluster of five, ten, even up to 40 or 50 hospitals. And often they'll place one instrument in the main lab or the central lab to get a feel for it.
And then they'll plan a rollout because the IDNs really like to standardize their care for all the patients that they serve, obviously to prevent differentiated outcomes for patients depending on which hospital you happen to go to.
So these planned rollouts we already work through with the customer; we have visibility on some of these. Obviously, the timing can vary as the customer wants to manage the training, and maybe some of the cost management and so on around it, capital planning.
But those impacts will start to show up even this year and definitely into 2027.
We have a couple of markets that we also expect to move with more pace.
Our partner Ameco in the greater Gulf region here maintains very close connections across the countries in that region. We have a number of evaluations that have already completed very successfully. We do expect those to now move into the contracting and deployment process here. And I think the very exciting thing is that there are a number of Ministries of Health for those countries that are reviewing it, along with other systems. And they will make some recommendations, guidelines, if you will, on adoption of Rapid AST and/or approving certain systems.
So we're very excited about those conversations. We think that market will have some very positive dynamics for us.
We recognize that Europe is going to continue to be slow but steady. We cannot ignore Europe.
We also, I think, have a duty to the European patients to keep pushing this technology. We recognize that many of the European countries are really struggling with hospital budgets.
And they tell us this.
There is a gap in their actionability, as they recognize, between stated objectives for their sepsis patients, stated country guidelines in some cases, and what they're really practically able to do with their budgets.
So one of our focuses here will be on helping them understand the real cost savings that come from this, helping visualize that. There's some studies being planned with customers driving that work themselves to try to motivate putting this technology in place because we see this as net cost saving and driving patient outcomes.
So that's Europe.
We don't expect it to have a major inflection during 2026, but it will keep a slow, steady background addition to our installed base.
And then we are very excited about new geographies coming online. We did announce something already with Bangladesh, so we're excited to put that in play early this year and start treating patients in Southeast Asia. And then there are a number of countries that are queued up in various stages, if you will, of conversation and readiness to deploy ASTar.
The AMR burden is very high in some countries and is not going away. So this is the underlying driver of our needs. Now, for Q-linea AB, we are a small company. We need to balance our resources and attention. We're having a very customer-led approach here.
So we engage closely when customers or very important Key Opinion Leaders and countries are keen to proceed.
And then we work with those flagship institutions or individuals on a plan for the overall country. And then the other thing we're excited about, that we will expect to kick in during 2026, is expanding our reach to nonblood infections.
Those are anything between two and three, or four times, the number of patients already in hospital. Not all nonblood infections require critical treatment. There's a large number that aren't, for example.
But again, many of them are.
And especially high susceptibility patient groups like pediatrics and cancer that I mentioned.
So during the second half of this year we plan to launch a dedicated kit and kit software for non-blood infections that will have positive economics for the patients, recognizing that their expectations here for non-blood are going to be different.
So that'll help us significantly. We think, and will be another milestone for us in our leadership in this market to drive that as well.
So all of those dynamics we see driving both the placements of instruments and the number of tests as we move through this year.
We're not alone in ringing this bell; we continue to be present at all the major conferences, at least in Europe and the US.
And in fact, I will be down with our head of EMEA, Franco, in Dubai next week for a large regional and global conference, to continue to reach out to the world for Q-linea AB, ASTar, and the broader rapid AST message.
We're very proud to state that we are making an outsized level of noise in the market vis-à-vis the size of our company.
The collaboration partners that we have are top KOLs in their countries, many of whom are driving their own papers and presentations.
They're working with our team here on this slide.
You see Vikas making a presentation at IDWeek in Q4 in Atlanta.
And Natalie here was also with Vikas in Las Vegas this month at AMARI, which is a very exciting place. It's a much more intimate setting with the types of colleagues and stakeholders that we're looking to reach.
And the themes are very consistent. We are presenting the outcomes from ASTar. We're presenting customer data. We're bringing new perspectives on how to use our technology, our platform. And that's being very positively received because Vikas's particular expertise in cancer care overlaps with AMR and continues to drive high-level discussions with KOLs in that regard.
And we see this as a really key patient group to focus on going forward. And in general, across our industry and our stakeholders, they continue to raise this topic consistently.
There's a very high interest in rapid AST, many of whom are putting forward the need in their institutions to reduce the time to actionable results from the diagnostic lab so that they can get patients on appropriate therapy. In parallel, more therapies are also coming from the pharmaceutical companies. And as they launch those, often at greater cost. And then, compared to standard treatments, there will be a growing need for diagnostic tools that help determine when these new drugs should be used. So there's a lot of trends, let's say, in the background that are driving the interest in rapid AST. And I won't get to the details of this, not least of which I'm far from qualified as Dr. Rebecca Yee and Dr. Vikas Gupta are to speak to the details of the science here, but this is an example of what's being presented from our customers on using ASTar in their environment. And we keep seeing the same things over and over. But we have to keep stating it over and over until it's accepted that ASTar is much, much faster than standard of care.
And that answer that comes faster is changing therapy in a high share of the patients in this particular case in George Washington University. When they look at the chart review, they would have made a change in 74% of the patients. In many cases, you're actually de-escalating the patient, which means you're giving them a more narrow antibiotic that has less side effects for the patient and significantly lowers the cost to the hospital as well. Or you could be moving them from an IV antibiotic to an oral antibiotic, which is much easier to administer. And often then you can either discharge the patient or move them into a lower cost ward of the hospital or a different treatment environment, again, significantly reducing costs. And it's great to see the customers putting numbers against these.
These are the types of things we will see from our LIFETIMES paper that we continue to work with. Our collaboration partners in Italy and other places like the UK are looking to do this on a more individual basis for groups of hospitals trying to put these things together to really show that this has material impact for patients and for the budgets. And it was really, I think personally, I was surprised to see how great the effect was here. They estimate that they could reduce their drug spending by more than 50% across the entire patient population by getting patients on appropriate therapy much more quickly.
As we like to say internally here, getting the third bag right, which is the third time you hang an IV bag, it needs to be the right one. And only rapid AST, and especially ASTar, can guarantee that.
And often for a patient, you're going to be on six, eight, 12 bags or so. So the more bags you save, the more money you save, and the fewer adverse events. So great to see that that point continue to be made by our customers.
So what do we see going forward? Focus for this year. This slide hopefully is visually familiar from before. We're not changing this too frequently, and our focus remains the same, but we put more and more clarity against it. So really continuing to emphasize the commercial activity here, for me, just simplifying it to an ASTar week.
We need to hit that number, exceed that number. And we are more than good for making our plan here. There is a sizable queue of former Accelerate Pheno platform users who have been left since Accelerate exited the market and its support was discontinued. Support for Pheno. So we're working across markets to engage those customers, many of whom are reaching out to us and trying to put in place a solution quickly so they do not have to lower the standard of care again for their patients.
So we're excited about that pipeline that's driving a lot of activity in the near term here. And then again, the first installations are going into Asia, and hopefully, also Latin America soon as well. And then once we've placed the box, not losing sight of the fact we need to keep engaging with customers and driving up the test per ASTar on a going basis. I mentioned earlier some of the dynamics there.
We also know that in some markets, again, budget-constrained labs are prioritizing these for their most critical patients, right? Using it for escalation, or for patients where they think the current empiric treatment might not work. They might die. That's entirely appropriate. It's a very positive effect to using ASTar. It's what motivates a lot of us here at Q-linea AB. However, also using it for the broader base of patients, as we just saw from the previous slide, the 74% of patients that can be changed in therapy, many of those are going the other direction and saving costs. So, as we engage with customers with more of that data, they take the bet, if you will, that using this slightly more expensive test will actually net save costs. That's what they're looking for. We provide that data and we will see continued increases in the per instrument use going forward. And, as I said, launching the Non-blood testing as well at the back end of this year. So that will drive volume, and our clinical and R&D teams are very focused clinically on the US version two menu, engaging with the FDA, making sure that everything they need to make a fully informed decision, which we do expect in the first half of this year, as I said.
And then, developing and launching that Non-blood testing kit. And then on the financial side, which will be a bridge here into Christopher. Our priorities remain the same, focusing on continued cost discipline. We've been trending down very nicely. I mentioned with the restructuring coming off the back of December last year. We're now in a much different cost position, which Christopher will talk to. So we're committing to keeping that at or below SEK 11.5 million as we go into Q1 and through 2026, and also maintaining a strong capital recovery as much as possible, just because we're a small company and need the financing, if you will, from this.
So trying to encourage the customers to pay in advance for the instrument. And of course, they get to see that benefit in a lower test price.
In fact, many of the institutions that are larger, especially in the US, this is a normal way of doing things. So as we see this normalizing or these IDN expansions happening, for example, they've already done one, they've tested it, and they want to go forward. We do think this will start to tilt towards much more capital sales, which will provide us a tailwind on our cash availability. We've already locked in some of the gross margin expansion that we expect, continuing to focus on delivering that and making sure the scale gains are real and achieved. And then the rest takes care of itself, if you will.
So on that note, I'll turn it over to Christopher.